Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2015-12-02 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2015
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30 November 2015, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements as required by the exchange. This type of document fits best under 'Capital/Financing Update' (CAP) as it provides updates on the company's capital structure changes and share issuance activities.
2015-12-02 English
VOLUNTARY ANNOUNCEMENT - FRAMEWORK AGREEMENT TO ACQUIRE TYPE 2 DIABETES DRUG MITGLINIDE FROM JIANGSU HANSOH
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Uni-Bio Science Group Limited regarding a framework agreement to acquire manufacturing technology and distribution rights for a diabetes drug, Mitiglinide, from Jiangsu Hansoh Pharmaceutical. It details the terms of the agreement, background information on the drug, the companies involved, and strategic reasons for the deal. There are no financial statements, quarterly or annual results, or regulatory filings such as audit reports or certifications. The content focuses on a business transaction related to acquisition and licensing of technology, which fits the category of Capital/Financing Update (CAP) as it involves a significant corporate transaction impacting the company's assets and business operations. The document is not a full report but an announcement of a material transaction. Therefore, the appropriate classification is CAP with high confidence.
2015-11-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2015
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31 October 2015, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements, typical for compliance with exchange rules. It is not an annual or interim report, earnings release, or management report. It is not a proxy, AGM material, or voting results announcement. The document fits the category of Share Issue/Capital Change (SHA) as it reports on share capital movements and related share issuance activities.
2015-11-05 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a listed issuer, Uni-Bio Science Group Limited, reporting changes in issued share capital and share buybacks. It includes detailed information on share issues and repurchases pursuant to specific listing rules of The Stock Exchange of Hong Kong Limited. The content focuses on share capital changes and repurchase activities, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document is not a full report but a regulatory disclosure of capital changes and share buybacks. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length (6314 characters) supports it being a substantive disclosure rather than a brief announcement or certification.
2015-10-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2015
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30 September 2015, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, typical of a capital or financing update. The document is lengthy (15,000 characters) and contains detailed data on share capital changes, not just an announcement or summary. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-10-02 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committees such as the Audit Committee, Remuneration Committee, and Nomination Committee. It is dated with effect from a specific date (18 September 2015). There is no financial data, no report content, no voting results, no legal proceedings, no capital changes, and no mention of any report publication or certification. The content is clearly about the composition and structure of the board and its committees, which fits the definition of Board/Management Information (MANG). The document length is short and focused solely on board members and their roles, confirming it is not a full report or announcement of a report. Therefore, the classification is MANG with high confidence.
2015-09-18 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.